For Residents

In the Pipeline for Psoriasis: Upcoming Psoriasis Treatments

Author and Disclosure Information

Psoriasis is a chronic debilitating disease in which dermatologists take a frontline role in improving the quality of life of affected patients. Although recent years have seen the advent of numerous new medications for the treatment of psoriasis, there still is considerable room for improvement in our treatment of this condition. Novel insights into the underlying mechanisms of psoriasis have yielded exciting new potential medications, many with promising preliminary efficacy data. The upcoming systemic agents for the treatment of psoriasis are presented in this article, encompassing novel biologics and small-molecule medicines (eg, IL-17 receptor blockers, Janus kinase [Jak] inhibitors). The underlying mechanisms and currently available data for each drug will be discussed to impart a working knowledge of these new treatment options to dermatology residents, as these drugs may soon be added to our armamentarium for treating psoriasis.


 

Next Article:

Polyarteritis nodosa gene discovery raises new possibilities for field

Related Articles

  • Blog

    Comorbidities: The List Grows

    There is a growing amount of literature demonstrating that psoriasis is a chronic and debilitating inflammatory disease associated with serious...

  • Blog

    Psoriasis: The Story Worsens

    We have already come a long way from thinking that psoriasis is merely a cutaneous disease caused by a defect in cellular replication; we now...

  • Blog

    Biosimilar Dilemma

    The passage of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) allowed for the creation of a regulatory pathway for new,...

  • Case Letter

    Psoriasis and Leprosy: A Mystifying Coexistence

    Psoriasis and leprosy exist mutually exclusively with only a few cases being reported regarding their coexistence. Among the various forms of...